COMP <GO>
HCM vs ABBV // GROSS PROFIT MARGIN
HUTCHMED (China) Limited (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: HCM 2
— ABBV 9
■ METRIC PARITY
LAST: $13.59 (+2.03%) • MKT CAP: $2.37B
gross-margins
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCM VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCM | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.50% | 29.00% | -31.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.32% | 3.47% | -6.79 | ABBV | /fcf-yield <GO> |
| Operating Margin | -7.10% | 24.60% | -31.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 6.90% | +61.10 | HCM | /net-margins <GO> |
| Revenue Growth (YoY) | -13.00% | 8.60% | -21.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.63 | 5.33 | -1.70 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.0 | 65.1 | -18.10 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 4.8x | 113.1x | -108.30 | HCM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.37B | $513.86B | -$511.49B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCM REV | ABBV REV | HCM GROSS % | ABBV GROSS % | HCM FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $548.5M | $61.16B | 38.7% | 70.2% | -$78.8M | $17.82B |
| FY 2024 | $630.2M | $56.33B | 44.6% | 70.0% | -$17.4M | $17.83B |
| FY 2023 | $838.0M | $54.32B | — | — | $219.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCM // BETA —
ABBV // BETA 1.15